BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32888176)

  • 1. Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4.
    Danek PJ; Basińska-Ziobroń A; Wójcikowski J; Daniel WA
    Pharmacol Rep; 2021 Feb; 73(1):303-308. PubMed ID: 32888176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.
    Basińska-Ziobroń A; Daniel WA; Wójcikowski J
    Pharmacol Rep; 2015 Dec; 67(6):1178-82. PubMed ID: 26481538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
    Danek PJ; Wójcikowski J; Daniel WA
    Toxicol Appl Pharmacol; 2020 Nov; 406():115239. PubMed ID: 32941854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application.
    Wójcikowski J; Basińska A; Daniel WA
    Biochem Pharmacol; 2014 Jul; 90(2):188-95. PubMed ID: 24841887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
    Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
    Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
    Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
    Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
    Danek PJ; Wójcikowski J; Daniel WA
    Pharmacol Rep; 2020 Dec; 72(6):1685-1694. PubMed ID: 32279279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
    Halladay JS; Wong S; Khojasteh SC; Grepper S
    J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
    Murray M; Zhang WV; Edwards RJ
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver.
    Daniel WA; Syrek M; Ryłko Z; Kot M
    Pol J Pharmacol; 2001; 53(6):615-21. PubMed ID: 11985335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.
    Garcia M; Rager J; Wang Q; Strab R; Hidalgo IJ; Owen A; Li J
    In Vitro Cell Dev Biol Anim; 2003; 39(7):283-7. PubMed ID: 14599235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
    Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
    Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
    Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
    Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study.
    Haduch A; Ogórka T; Boksa J; Daniel WA
    Pharmacol Rep; 2005; 57(6):872-7. PubMed ID: 16382211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
    Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
    Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
    Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
    J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.
    Reinach B; de Sousa G; Dostert P; Ings R; Gugenheim J; Rahmani R
    Chem Biol Interact; 1999 Jun; 121(1):37-48. PubMed ID: 10418969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP-mediated clozapine interactions: how predictable are they?
    Chetty M; Murray M
    Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.